Zota Health Care Q2FY26 FY25-26 – 310 Davaindia Stores in One Quarter, 2,055 Total, ROE -36%, Still Selling Generics Like iPhones
1. At a Glance
Zota Health Care Ltd, the parent of Davaindia generic pharmacy chain, just went full Reliance-style expansion. In Q2FY26 alone, they opened 310 new Davaindia stores — 221 COCO and 89 FOFO — taking the total to 2,055 stores.
Stock trades at ₹1,439, market cap ₹4,362 Cr. Numbers are, well, otherworldly: ROE -36%, ROCE -17%, OPM -0.16%, PAT = -₹58 Cr TTM. Still, stock gave +126% return in last 1 year. Investors are basically treating loss-making pharmacies like Tesla charging stations.
2. Introduction
Picture this: a company selling generic medicines at 30–90% discount — something middle-class India has always wanted. Now scale it up to 2,055 stores across 24 states. Sounds like a dream, right?
But dreams don’t pay rent. Zota’s Davaindia expansion is fuelled by QIPs, preferential allotments, and fundraises. Their P&L looks like an IPL franchise — huge fan following, massive branding, Kapil Dev as ambassador, but no actual profits.
The irony? They are in healthcare but their balance sheet looks like a patient on ventilator support.
3. Business Model – WTF Do They Even Do?
Three pillars:
Domestic Pharma Distribution (49%) → Traditional B2B generics & OTC distribution with 1,050+ distributors.
Davaindia Retail (22% in FY21, much bigger now) → Asset-light franchise model selling private-label generics (95%+ of sales). They give “branded generics” a reality check.
Exports (29%) → 30+ countries, especially Africa & Latin America.
USP = cheap generics. Customers save, franchisees scale, Zota dreams. Davaindia is the crown jewel, but it’s also cash-hungry.
So basically, they are India’s DMart of medicines, except instead of profits, they distribute discounts.
4. Financials Overview
Quarterly Snapshot
Source table
Metric
Q2FY26
Q2FY25
Q1FY26
YoY %
QoQ %
Revenue (₹ Cr)
104
67
97
+84%
+7%
PAT (₹ Cr)
-14.3
-12.6
-13.0
-13%
-10%
EPS (₹)
-4.81
-4.41
-4.50
N/A
N/A
Annualized EPS = negative. P/E = not meaningful.
Commentary: Topline booming, losses deeper than Kapil Dev’s cricket records.
5. Valuation Discussion – Fair Value Range
a) P/E Method
Not meaningful (loss-making).
b) EV/EBITDA Method
EBITDA negative in many quarters. Valuation model = broken
